CTLA4 and melanoma: For example, it has been demonstrated that an increased frequency of blood-circulating ICOS+ CD4+ T cells, sustained over a period of 12 weeks of anti-CTLA-4 therapy, correlates with favorable clinical outcome in melanoma patients.